Surgeons at Rush University Medical Center in Chicago have placed an experimental brain implant meant to give a crude form of sight to a third person with total blindness, the hospital said on October 29, 20261. The device skips the eyes and the optic nerves altogether and connects directly to the visual cortex, the area at the back of the brain that handles vision1. It is called the intracortical visual prosthesis, or ICVP: “intracortical” means it sits inside the brain’s outer layer, and a “prosthesis” is a device that replaces a lost body function1.
The surgery is a step in an early study, not a result. The sources available do not include any published findings on what the volunteers can see with the device.
What happened
In this week’s operation, the team implanted 34 tiny wireless stimulators carrying a total of 544 electrodes, the thin contacts that deliver small electrical pulses to brain cells1. The surgeon was Sepehr Sani, a Rush professor of neurological surgery1.
“The success of this third implantation of the ICVP represents an important step forward in offering a meaningful option for patients with profound vision loss.”
Sani said that in the Rush announcement1. The project’s leader, Philip R. Troyk of the Illinois Institute of Technology (Illinois Tech), said the third implantation shows the system’s “scalability and robustness”2.
One point on timing: an eye-care news outlet reported the third implantation, with the same 34 stimulators and 544 electrodes, in an article dated May 11, 20262. Rush’s own announcement is dated October 29, 2026 and describes the surgery as taking place “this week”1. The sources do not explain the difference.
The new implant is larger than the first one. In February 2022, Rush neurosurgeon Richard Byrne implanted 25 stimulators with 400 electrodes in the study’s first participant3. The available sources give no details about the second participant.
How the device is meant to work
Many people with total blindness have damaged retinas (the light-sensing layer at the back of the eye) or optic nerves, but their visual cortex is still intact4. For them, a device that talks to the brain directly may be the only kind of advanced sight aid they could use, the developers say4. This sets it apart from retinal implants, which need parts of the retina and the optic nerve to still work2.
The system uses a video camera to capture images5. Each small implanted unit, called a wireless floating microelectrode array, gets its power and its commands over a wireless link, so no wires or connectors pass through the scalp5. By sending commands to these units, the system passes camera images to the brain, “creating a crude visual perception of the image,” according to the project page run by the Chicago Lighthouse, a partner organization5.
The same page is plain about the limits: “While the perceptions will not be like normal vision, they may be of benefit to the user for performing visually guided tasks”5. Earlier work in this field describes such perceptions as points of light, called phosphenes, that can form low-resolution dot patterns6.
The team says the ICVP is the first system of its kind to use a group of fully implanted, miniaturized wireless stimulators1. Because the units can stay in permanently, researchers have time to study how the device works and recipients have time to learn how to use it1.
What this news does not show
A successful surgery means the device was placed as planned. It does not tell us how well people see with it, how safe it is over years, or whether it helps in daily life. The study’s own goal is to test whether the implant gives participants a better ability to move around and do basic tasks guided by sight1.
The trial is listed by Rush as a phase 1 study, the first and smallest stage of testing in people, meant to check safety and feasibility (whether the approach can work at all)7. Participants are followed for one to three years after implantation2. After about a month of recovery, testing takes place at the Chicago Lighthouse’s Hilton Center for Prosthetic Research2.
The study also screens out people who expect their sight to return to what it was before they went blind7. The device is not approved for treatment; a reference source notes that, as of 2025, such devices had not been approved by the US Food and Drug Administration and were still experimental6.
Who is behind it and who pays
Illinois Tech leads the work, with Troyk, executive director of its Pritzker Institute of Biomedical Science and Engineering, as principal investigator1. The device reflects nearly three decades of research by the team1. Partners include Rush, the Chicago Lighthouse, the Wilmer Eye Institute at Johns Hopkins, the University of Texas at Dallas, the University of Chicago, and two companies, Microprobes for Life Science and Sigenics Inc.1.
The US National Institutes of Health awarded $2.5 million for the first year of a three-year project to begin the clinical trial, through its BRAIN Initiative, a federal program for brain technology research4. A 2022 report on the first implant said funding also came from the Department of Defense and private donors3. Most of what is known about the device so far comes from the institutions running the study.
Troyk said the team is also pursuing uses of the brain interface for other conditions, including in the spinal cord1.
How it fits the field
Stimulating the visual cortex to create sight is not new. In 1978, researcher William Dobelle placed 68 electrodes in the visual cortex of a blind person and produced phosphenes6. In 2020, researchers placed 1,024 electrodes in the visual cortex of macaque monkeys, which then told simple shapes apart through electrical stimulation alone; that was an animal study6. A major remaining hurdle has been building wireless systems safe enough for long-term use in people6, which is the problem the ICVP team set out to address.
Other groups have also produced visual perceptions in blind volunteers by stimulating the cortex2. The ICVP stands out mainly for its fully wireless, implanted design, according to the team8.
What to watch next
- Published results. Data on what the three recipients perceive, how well they navigate, and any side effects would be the first real measure of the approach.
- More volunteers. The study is still recruiting1. Rush lists eligibility as ages 18 to 65, no or bare light perception in each eye with no hope of improvement from approved treatments, normal or near-normal vision during at least the first 10 years of life, and at least one year of adjustment to blindness7.
- Long-term safety. Since the units are meant to stay in permanently, how they hold up over the one- to three-year follow-up will matter2.
“For people who are completely blind, even the ability to perceive a small amount of light can profoundly impact their daily lives,” said Janet P. Szlyk, president and CEO of the Chicago Lighthouse1. Whether this device delivers that, and how much more, is what the study is meant to find out.
